Meeting
2011 ASCO Annual Meeting
A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen.
Authors
S. Kim
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
S. Kim , J. Lee , Y. Joo , H. Kim , H. Ryoo , M. K. Kim , G. Lee , J. Lee , W. Lee , J. H. Park , S. H. Bae , M. S. Hyun , D. Kim , Y. J. Min
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Allogeneic Bone Marrow
Clinical Trial Registration Number
NCT00774280
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6524)
Abstract #
6524
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.
First Author: Uday R. Popat
Poster
2012 ASCO Annual Meeting
Allogeneic stem cell transplantation for patients over age 65 with acute myelogenous leukemia and myelodysplastic syndrome.
First Author: Henry Jacob Conter
Poster
2019 ASCO Annual Meeting
A phase II study of myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT) for acute lymphoblastic leukemia (ALL) in older patients using fludarabine and total body irradiation (Flu/TBI).
First Author: Omer Hassan JAMY
Poster
2018 ASCO Annual Meeting
Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.
First Author: Dietger Niederwieser